Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

World Journal of Gastroenterology

Volumn 19, Issue 14, 2013, Pages 2171-2178

  He, Chao ^a   Bian, Xue Yi ^a   Ni, Xing Zhi ^a   Shen, Dan Ping ^a   Shen, Yan Ying ^a   Liu, Hua ^a   Shen, Zhi Yong ^a   Liu, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clinicopathological characteristics; Gastric cancer; Gene amplification; Human epidermal growth factor receptor 2; Protein expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; FOLLOW UP; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER;

EID: 84876371807     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i14.2171     Document Type: Article

References (36)

1. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275 [PMID: 20385184 DOI: 10.1016/j.jconrel.2010.04.009]
2. Kaur A, Dasanu CA. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother 2011; 12: 2493-2503 [PMID: 21967344 DOI: 10.1517/14656566.2011.605354]
3. Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B, Cocquyt V, Denys H, Pauwels P, Libbrecht L. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol 2011; 64: 200-207 [PMID: 21177747 DOI: 10.1136/ jcp.2010.084863]
4. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011; 11: 277 [PMID: 21708009 DOI: 10.1186/1471-2407-11-277]
5. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 2011; 64: 1097-1101 [PMID: 21896578 DOI: 10.1136/jclinpath-2011-200082]
6. Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol 2011; 64: 880-883 [PMID: 21757431 DOI: 10.1136/jclinpath-2011-200009]
7. Reichelt U, Duesedau P, Tsourlakis MCH, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-129 [PMID: 17143264 DOI: 10.1038/modpathol.3800712]
8. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 2011; 7: 187-199 [PMID: 21345138 DOI: 10.2217/fon.10.178]
9. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
10. Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 2011; 19: 506-508 [PMID: 22089490 DOI: 10.1097/ PAI.0b013e31822c3a0f]
11. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-59 [PMID: 21169738 DOI: 10.1097/PAP.0b013e3182026d72]
12. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-958 [PMID: 2430175]
13. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, Kuroki T, Kano K. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986; 77: 1047-1052 [PMID: 3464796]
14. Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol 2011; 23: 396-402 [PMID: 21505336 DOI: 10.1097/CCO.0b013e3283469567]
15. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33 [PMID: 20185938 DOI: 10.1159/000288295]
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43 [PMID: 19548375]
17. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9: 1543-1551 [PMID: 19916733 DOI: 10.1517/14712590903439702]
18. Fujita T. Trastuzumab for gastric cancer treatment. Lancet 2010; 376: 1735; author reply 1735-1736 [PMID: 21093641]
19. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805 [PMID: 17031648 DOI: 10.1007/s00280-006-0337-z]
20. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95 [PMID: 18097546]
21. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51 [PMID: 17611206 DOI: 10.1056/NEJMra043186]
22. Lange T, Nentwich MF, Lüth M, Yekebas E, Schumacher U. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. Cancer Lett 2011; 308: 54-61 [PMID: 21570176 DOI: 10.1016/j.canlet.2011.04.013]
23. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010; 70: 2259-2267 [PMID: 21080742 DOI: 10.2165/11205900-000000000-00000]
24. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, Gullick WJ, Filipe MI. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991; 64: 79-83 [PMID: 1677259 DOI: 10.1038/bjc.1991.243]
25. Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H, Tahara E. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50: 8002-8009 [PMID: 1979253]
26. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71 [PMID: 16328035]
27. Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135: 1460-1465 [PMID: 22032573 DOI: 10.5858/arpa.2010-0541-OA]
28. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
29. Tsapralis D, Panayiotides I, Peros G, Liakakos T, Karamitopoulou E. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol 2012; 18: 150-155 [PMID: 22253521 DOI: 10.3748/wjg.v18.i2.150]
30. Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol 2012; 46: e31-e37 [PMID: 22064554 DOI: 10.1097/ MCG.0b013e31823457ea]
31. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-777 [PMID: 19269014 DOI: 10.1016/j.humpath.2008.11.014]
32. Ananiev J, Gulubova M, Manolova I, Tchernev G. Prognostic significance of HER2/neu expression in gastric cancer. Wien Klin Wochenschr 2011; 123: 450-454 [PMID: 21739203 DOI: 10.1007/s00508-011-0025-9]
33. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer-A Systematic Analysis of Data from the Literature. J Cancer 2012; 3: 137-144 [PMID: 22481979 DOI: 10.7150/jca.4090]
34. Bouché O, Penault-Llorca F. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer 2010; 97: 1429-1440 [PMID: 21134821]
35. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH, Du YQ. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011; 17: 1501-1506 [PMID: 21472111 DOI: 10.3748/wjg.v17.i11.1501]
36. Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol 2012; 18: 2402-2407 [PMID: 22654433 DOI: 10.3748/ wjg.v18.i19.2402]